ProCE Banner Activity

monarchE 5-Yr Outcomes: Adjuvant Abemaciclib Plus ET in Patients With High-Risk, Node-Positive HR+/HER2- EBC

Conference Coverage

Updated data from the randomized phase III monarchE trial continue to show consistent iDFS and DRFS benefits through 5 years with adjuvant abemaciclib plus ET and improved responses vs ET alone in patients with high-risk, node-positive, HR+/HER2- early breast cancer.

Released: October 23, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc